Royalty Pharma PLC $RPRX Shares Acquired by Tredje AP fonden

Tredje AP fonden lifted its position in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 44.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 53,464 shares of the biopharmaceutical company’s stock after acquiring an additional 16,545 shares during the period. Tredje AP fonden’s holdings in Royalty Pharma were worth $2,066,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Handelsbanken Fonder AB lifted its position in shares of Royalty Pharma by 21.6% during the 4th quarter. Handelsbanken Fonder AB now owns 315,686 shares of the biopharmaceutical company’s stock valued at $12,198,000 after buying an additional 56,061 shares in the last quarter. Resona Asset Management Co. Ltd. lifted its position in shares of Royalty Pharma by 0.4% during the 4th quarter. Resona Asset Management Co. Ltd. now owns 114,910 shares of the biopharmaceutical company’s stock valued at $4,440,000 after buying an additional 474 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of Royalty Pharma by 22.5% during the 4th quarter. ProShare Advisors LLC now owns 18,871 shares of the biopharmaceutical company’s stock valued at $729,000 after buying an additional 3,462 shares in the last quarter. HighTower Advisors LLC lifted its position in shares of Royalty Pharma by 27.8% during the 4th quarter. HighTower Advisors LLC now owns 281,122 shares of the biopharmaceutical company’s stock valued at $10,863,000 after buying an additional 61,166 shares in the last quarter. Finally, North Dakota State Investment Board purchased a new position in shares of Royalty Pharma during the 4th quarter valued at approximately $516,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

Insiders Place Their Bets

In other Royalty Pharma news, Director Gregory Norden sold 3,045 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $53.00, for a total value of $161,385.00. Following the completion of the sale, the director directly owned 191,803 shares of the company’s stock, valued at $10,165,559. This trade represents a 1.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 34,791 shares of the firm’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $49.78, for a total value of $1,731,895.98. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 155,893 shares of company stock valued at $7,512,360 in the last three months. 18.84% of the stock is currently owned by insiders.

Analyst Ratings Changes

RPRX has been the topic of a number of recent analyst reports. Morgan Stanley increased their target price on Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a research report on Friday, April 10th. Citigroup increased their target price on Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Weiss Ratings lowered Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 15th. JPMorgan Chase & Co. increased their target price on Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Finally, UBS Group increased their target price on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, April 21st. Seven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $53.71.

Royalty Pharma Trading Up 1.2%

Shares of RPRX stock opened at $53.06 on Thursday. The stock’s fifty day moving average is $48.72 and its two-hundred day moving average is $43.73. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.66 and a current ratio of 2.66. The firm has a market capitalization of $30.55 billion, a P/E ratio of 36.10, a PEG ratio of 1.44 and a beta of 0.40. Royalty Pharma PLC has a fifty-two week low of $32.15 and a fifty-two week high of $53.47.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The business had revenue of $631.00 million during the quarter, compared to the consensus estimate of $881.69 million. Research analysts expect that Royalty Pharma PLC will post 5.05 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $0.235 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.8%. Royalty Pharma’s dividend payout ratio (DPR) is 63.95%.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.